# A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

> **NCT05169489** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **BIOLOGICAL:** bbT369

## Key facts

- **NCT ID:** NCT05169489
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-24
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-09-19
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169489, "A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05169489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*